BO-112 is under clinical development by Highlight Therapeutics and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BO-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BO-112 overview

BO-112 is under development for the treatment of aggressive solid tumors including metastasis from refractory non-small cell lung cancer, gastric cancer, gastroesophageal junction cancer, basal cell carcinoma, soft tissue sarcoma and hepatocellular carcinoma, renal cell carcinoma, leiomyosarcoma and squamous cell carcinoma of the head and neck. It is administered through intratumoral  and intralesional route. The drug candidate is a synthetic double-stranded RNA (dsRNA) polyinosinic:polycytidylic acid (poly I:C) nanoplexed with the cationic carrier polyethylenimine (PEI), it activates retinoic acid inducible gene 1 protein (RIG 1), toll like receptor 3 (TLR 3) and melanoma differentiation associated protein 5 (MDA5).

It was also under development for the treatment of melanoma, triple negative breast cancer, gastric cancer, gastroesophageal junction cancer, colorectal cancer and neuroendocrine tumors.

Highlight Therapeutics overview

Highlight Therapeutics is a clinical-stage immune-oncology company that conducts develops RNA-based therapies. The company’s pipeline product includes BO-112 that induces immunogenic cell death in solid tumors and simultaneously activates the immune system to certify optimal antigen processing and presentation to the adaptive immune system. Its BO-112 product is currently being investigated in clinical trials as a monotherapy and in combination with checkpoint inhibitors. Highlight Therapeutics’s services include formulation, preclinical development, manufacturing, and clinical trials. The company develops RNA-based therapies against validated and novel targets in cancer and immune cells. It operates in Madrid and Valencia, Spain. Highlight Therapeutics is headquartered in Paterna, Spain.

For a complete picture of BO-112’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.